ArticleStem cell research & therapy2025
Engineering a controlled cardiac multilineage co-differentiation process using statistical design of experiments.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developmentally Inspired Bioprinting of Nascent Multicellular Human Heart Tissue Through In Situ Differentiation and Morphogenesis of iPSCs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe heart is a complex organ composed of diverse cell types, whose interplay is crucial for development, tissue homeostasis, and disease progression. A potential approach to recapitulate this heterotypic multicellular environment is the co-differentiation of induced pluripotent stem cells (iPSCs) into multiple cardiac cell types, facilitating the unlocking of their full potential for regenerative medicine and drug development. However, the inherent complexity of co-differentiation, where multiple differentiation factors simultaneously influence the induction of multiple cell types, presents a significant challenge in achieving high controllability over the process toward the desired outcome. Thus, a robust strategy is essential for engineering a controlled co-differentiation process with broader applicability.
methodsGiven the importance of heterotypic cellular proportions in facilitating proper interactions, we present a new strategy to engineer a controlled cardiac co-differentiation process from iPSCs using statistical design of experiments to simultaneously generate cardiomyocytes, mural cells, and endothelial cells, which are major constituents of the heart.
resultsWe divided the process into two stages: progenitor cell induction and the subsequent trilineage co-differentiation, allowing for stage-specific optimization. Given that the performance of progenitor cell induction may critically influence the overall process performance, we carefully optimized activin A and CHIR-99021 using the sequential design of experiments to achieve approximately 95% induction efficiency of KDR+/PDGFR-α+ cardiogenic mesoderm cells from iPSCs with minimal batch-to-batch variability. In the trilineage co-differentiation stage, we developed unique multi-response models to delineate trilineage co-differentiation ratios within a defined parameter space of WNT signal inhibitor and vascular endothelial growth factor. This enabled the identification of potential conditions that steer co-differentiation toward desired cellular constitutions, a critical factor of effective cellular interplays. Repeated trilineage co-differentiation experiments confirmed the high process controllability, with a close match between actual and predicted differentiation ratios. Furthermore, cardiomyocytes from trilineage co-differentiation exhibited a more mature sarcomere gene expression profile than those from monolineage differentiation.
conclusionsThese results highlight the effectiveness of our strategy for engineering a stem cell co-differentiation process and its applicability where multicellular interactions are crucial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.